866-997-4948(US-Canada Toll Free)

Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Head and Neck Cancer

No. of Pages : 151 Pages

 

Global Markets Directs, \'Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. 

 

It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma. Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer Squamous Cell Carcinoma.
  • A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Head And Neck Cancer Squamous Cell Carcinoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma 11
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies 13
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Development by Companies 22
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development 25
Amgen Inc. 25
AstraZeneca PLC 26
Eli Lilly and Company 27
Viralytics Ltd. 28
GlaxoSmithKline plc 29
Gilead Sciences, Inc. 30
Celltrion, Inc. 31
Novartis AG 32
Pfizer Inc. 33
Cell Therapeutics, Inc. 34
Merck KGaA 35
Idera Pharmaceuticals, Inc. 36
Cleveland BioLabs, Inc. 37
Oncolytics Biotech Inc. 38
Oncothyreon Inc 39
PCI Biotech Holding ASA 40
Acceleron Pharma, Inc. 41
Crusade Laboratories Limited 42
Ascenta Therapeutics, Inc. 43
VentiRx Pharmaceuticals, Inc. 44
Gliknik, Inc. 45
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
IMO-2055 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cetuximab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
cetuximab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
vandetanib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
brostallicin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
dacomitinib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dalantercept - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PC-A11 + [bleomycin sulfate] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Sym-004 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
entolimod - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
panitumumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CVA-21 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
lapatinib ditosylate - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
AT-101 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
bevacizumab + [cisplatin] + [docetaxel] + [fluorouracil] - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
everolimus - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Reolysin + [carboplatin] + [paclitaxel] - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
cixutumumab + [cetuximab] - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
nimotuzumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
PX-866 + [docetaxel] - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
vvDD-CDSR - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
bevacizumab + [docetaxel] - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
nimotuzumab + Radiation Therapy - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
lenalidomide + [cetuximab] - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
LY-2606368 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
vandetanib + [cisplatin] + Radiation Therapy - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Raltegravir + Cisplatin - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
bevacizumab + [cetuximab] - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
PX-866 + [cetuximab] - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
cetuximab biosimilar - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
bevacizumab + [cetuximab] + [cisplatin] + Radiation Therapy - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
VTX-2337 + [cetuximab] - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Anti-CD-147 Antibody - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
nimorazole + Radiotherapy - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
LJM-716 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
olaparib + [cetuximab] - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Seprehvir - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
GL-0810 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
GL-0817 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 126
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 146
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 147
 

Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Table


Number of Products Under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2013 11
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Amgen Inc., H1 2013 25
AstraZeneca PLC, H1 2013 26
Eli Lilly and Company, H1 2013 27
Viralytics Ltd., H1 2013 28
GlaxoSmithKline plc, H1 2013 29
Gilead Sciences, Inc., H1 2013 30
Celltrion, Inc., H1 2013 31
Novartis AG, H1 2013 32
Pfizer Inc., H1 2013 33
Cell Therapeutics, Inc., H1 2013 34
Merck KGaA, H1 2013 35
Idera Pharmaceuticals, Inc., H1 2013 36
Cleveland BioLabs, Inc., H1 2013 37
Oncolytics Biotech Inc., H1 2013 38
Oncothyreon Inc, H1 2013 39
PCI Biotech Holding ASA, H1 2013 40
Acceleron Pharma, Inc., H1 2013 41
Crusade Laboratories Limited, H1 2013 42
Ascenta Therapeutics, Inc., H1 2013 43
VentiRx Pharmaceuticals, Inc., H1 2013 44
Gliknik, Inc., H1 2013 45
Assessment by Monotherapy Products, H1 2013 46
Assessment by Combination Products, H1 2013 47
Assessment by Stage and Route of Administration, H1 2013 49
Assessment by Stage and Molecule Type, H1 2013 51
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 126
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 146
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Dormant Products 147
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..1) 148
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Dormant Products (Contd..2) 149

List of Chart


Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2013 11
Products under Development for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 46
Assessment by Combination Products, H1 2013 47
Assessment by Route of Administration, H1 2013 48
Assessment by Stage and Route of Administration, H1 2013 49
Assessment by Molecule Type, H1 2013 50
Assessment by Stage and Molecule Type, H1 2013 51

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *